Therapeutic Areas: Nephrology | Urology | Family Medicine

Benign Prostatic Hyperplasia (Enlarged Prostate) Clinical Trials

A listing of Benign Prostatic Hyperplasia (Enlarged Prostate) medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Florida

South Florida Medical Research
Aventura Florida 33180

Study to investigate the efficacy and safety of an investigational medication in the treatment of nocturia in men with BPH (prostate enlargement)

Clinical Research of South Florida
Coral Gables Florida 33134

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia (BPH)

Indiana

First Urology, PSC
Jeffersonville Indiana 47130

A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)

First Urology, PSC
Jeffersonville Indiana 47130

Confirm the efficacy of PRX302 in reducing lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH).

Kansas

Via Christi Research
Wichita Kansas 67214

Urology: OverActive Bladder

Massachusetts

Boston Clinical Trials
Roslindale Massachusetts 02131

A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)

New Mexico

New York

Pennsylvania

Urologic Consultants of Southeastern Pennsylvania
Bala Cynwyd Pennsylvania 19004

A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH). Clinical trial NCT02326454, MR901.